You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. AAV Mediated Gene Transfer to the CNS for MPS I

    SBC: REGENX BIOSCIENCES, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Mucopolysaccharidosis type I (MPS I) is an autosomal recessive storage disease caused by the absence of a-L-iduronidase (IDUA), resulting in systemic accumulation of glycosaminoglycan (GAG) storage materials, hepatosplenomegaly, skeletal dysplasias, cardiopulmonary obstruction, progressive neurologic impairment and death by age 15. MPS I is currently treated b ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  2. A Dual Molecular/Targeting Therapy for PanCa

    SBC: SYNERGENE THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Approximately 30,000 people in the United States are diagnosed each year with pancreatic Cancer (PanCa). Over 90% of these will die of the disease making PanCa one of the most devastating human malignancies. The current 5-year survival rate of less than 4% has changed little in the last 20 years despite improvements in therapy including the introduction of chem ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  3. A Dual Molecular/Tumor Targeting Therapy for PanCa

    SBC: SYNERGENE THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Approximately 30,000 people in the United States are diagnosed each year with pancreatic cancer (PanCa). Over 90% of these will die of the disease making PanCa one of the most devastating human malignancies. The current 5-year survival rate of less than 4% has changed little in the last 20 years despite improvements in therapy including the introduction of ...

    STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  4. Alpha-1 Antitrypsin Gene Therapy for Cystic Fibrosis

    SBC: Generx+, Inc.            Topic: N/A

    DESCRIPTION (Applicant's Abstract): The investigators have developed a plasmid vector that expresses the normal human alpha-1 antitrypsin (AAT) gene in human respiratory epithelium when delivered as a plasmid-cationic liposome complex. In subjects with inherited AAT deficiency, they showed that liposome mediated transfer of the normal AAT gene to the nasal respiratory epi ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  5. An Advanced Biosensor for Molecular Interaction Studies

    SBC: MOLECULAR SENSING, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Molecular interactions are central to the understanding of basic biology and cellular function, are paramount to all molecular assays (research and in vitro diagnostics), are essential in biomarker discovery and critical toward evaluating therapeutics. However, the tools available to quantify these interactions have limitations, in so far as they either rely up ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. An Advanced Biosensor for Molecular Interaction Studies.

    SBC: MOLECULAR SENSING, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Molecular interactions form the foundation of biology and chemistry. They are central to life itself and determine catalytic activity, cellular function, and therapeutic efficacy. The vast majority of diagnostic procedures depend on some type of specific molecular interaction. Therefore, the ability to perform pure liquid-phase molecular binding analysis at hi ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. An Enzyme Linked Immunosorbent Assay (ELISA) for Monitoring Galactosemia

    SBC: VANDALIA RESEARCH, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The long term objective of this proposal is to develop a diagnostic kit for monitoring nonenzymatically galactated proteins in galactose. Classical galactose is a disorder of galactose metabolism caused by a deficiency of galactose-1-phosphate uridyltransferase. The resulting severe impairment of galactose metabolism has been recognized for half a century and t ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  8. An Immersive Virtual Reality Peer Support Application for Individuals with Opioid Use Disorder: Development and Initial Evaluation

    SBC: Very Real Help, LLC            Topic: NIDA

    PROJECT SUMMARY Drug overdoses are the leading cause of death in the United States with approximately 72,000 people dying from drug overdose in 2017. Many of these fatalities occurred in individuals with opioid use disorder (OUD), which is one of the greatest public health issues confronting the United States today. Digital Recovery Support Services (DRSs) that include peer support, psychoeducatio ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Antiatherogenic Properties of tert-Butylhydroquinone

    SBC: BIOINVENTIONS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Atherosclerosis is the underlying cause of most cardiovascular disease and considerable evidence supports the role of hypercholesterolemia as a risk factor for this disease. In preliminary work, we found that tertiary-butyl hydroquinone (TBHQ), at a dose lower than approved for human use, was effective in reducing plasma levels of both total cholesterol and tri ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  10. A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: 300

    DESCRIPTION provided by applicant Problem Lower gastrointestinal bleeding is a significant medical problem in the United States accounting for more than hospital admissions and tens of billions of dollars of healthcare spending annually It is common for bleeding from a single site to stop and restart multiple times The three modalities now used to diagnose and locate gastrointestina ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government